CARLSBAD, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the pricing of an underwritten public offering of 3,214,285 shares of its common stock at an offering price of $2.80 per share. The gross proceeds to Signal from this offering are expected to be approximately $9,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to an additional 482,142 shares of common stock to cover over-allotments, if any. The offering is expected to close on February 20, 2015, subject to customary closing conditions.
Aegis Capital Corp. and Chardan Capital Markets, LLC are acting as joint book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 17, 2015.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: email@example.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.
CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 firstname.lastname@example.org
Source:Signal Genetics, Inc.